Latest Breaking News On - Stemcell systems - Page 1 : comparemela.com

FDA Grants RenovaCare Full IDE Approval for Safety and Feasibility Clinical Trial May 06, 2021 08:30 ET | Source: RenovaCare, Inc. RenovaCare, Inc. Roseland, New Jersey, UNITED STATES ROSELAND, N.J., May 06, 2021 (GLOBE NEWSWIRE) RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced that its Investigational Device Exemption (IDE) application has been granted full approval by the U.S. Food and Drug Administration (FDA). This approval enables RenovaCare to conduct a clinical trial to evaluate the safety and feasibility of its SkinGun™ and CellMist™ System for the treatment of burn wounds using skin cells obtained directly from the burn patient. “This marks the first FDA approval of a RenovaCare-sponsored regulatory submission, which is an important inflection point for our company and all our stakeholders,” commented Dr. Robin A. Robinson, RenovaCare Chief Scientific Officer and former director of the

United statesRobina robinsonKaiyo neddRenovacare cellmistRenovacare skingunAmit singhInnovation centerBiomedical advanced researchDrug administrationDevelopment authorityRenovacare incCompany skingunRenovacare rd innovation centerInvestigational device exemptionRenovacare chief scientific officerElectronic skingun